Key facts
- It has raised $5.5M across 2 recorded rounds; the latest was Early Stage VC ($5.5M) in Nov 2025.
- P1 Trials has filed 2 Form Ds with the SEC, most recently Dec 2025 ($5.5M sold to 1 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for P1 Trials
Funding rounds
2 roundsAbout P1 Trials
Developer of clinical trial support services designed for early-phase oncology research purposes. The company's platform provides centralized feasibility evaluation, regulatory coordination, contract and budget management, and financial administration for community-based oncology clinics, enabling clinical practices to undertake complex Phase 1 studies with structured operational support, consistent data handling, and improved access to investigational research opportunities for patients within local care settings.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2024
- Employees
- 5
- Website
- p1trials.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
P1 Trials doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in P1 Trials shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on P1 Trials in its N-PORT filings yet. We sweep new filings monthly.